2026-10-25
Apellis Pharmaceuticals, clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
NAS100 29,403 −1.38%
S&P 7,720 −0.30%
GOLD $3,993 −0.95%
BTC $78,307 +0.68%
VIX 17.20 +1.71%
latest tape · as of 07:23 UTC
The Screen · Healthcare · Biotechnology
Apellis Pharmaceuticals, Inc.
APLS · Nasdaq · USD · Market cap $5.3B · 733 employees
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs.
Not yet scored41.03 USD
Price as of 19 Jul 2026Daily close, not a live quoteLast reviewed 103 days ago
Screened 2026-07-19 · the tape above runs as of 07:23 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price41.03 USD at the 19 Jul 2026 close
- Our ratingFair value, current read accumulation
- Ethical screenNot yet scored
- Last reviewed19 Jul 2026 (103 days ago)
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 41.03 against the desk's fair-value range, base estimate 41.00, over the last year.
- Trend Accumulation
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical screen not yet scored
Price41.03 USD
Fair value41.00
Ethical score93.6/100
RatingFAIR VALUE
Our investment reviews on this name
2026-07-02Read Accumulation41.03+0.0% to today ✓First review on file: Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The full research record, in depth, below
This name holds its accumulation label.
Apellis Pharmaceuticals, Inc. holds its Accumulation at $41.03. Elevated stress, defensive posture warranted, held for 12 days.
| Phase | Accumulation |
| Quantitative state | Elevated stress, defensive posture warranted, held for 12 days |
| Price at the screen | $41.03 |
| Valuation | 38.35 trailing · -130.55 forward price to earnings |
| Values screen | Not scored · score 93.6 |
| Beta | -0.25 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 9.06% | Below 33% | Interest-bearing debt is just 9.1% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 7.73% | Below 33% | Cash held in interest-bearing accounts and securities is 7.7% of assets, under the one-third limit. | Pass |
| Receivables | 0.00% | Below 49% | Money owed to the company is 0.0% of assets, under the 49% limit. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadThe Read, in Plain English
Apellis Pharmaceuticals, clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 2026-10-29. It updates when the underlying figures move, and past reads are kept below.
2026-09-24
Clears
Apellis Pharmaceuticals, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 9%, inside the ~33% line, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
What the Numbers Say It Is WorthThe Fair Value Range
Our analysis reads FAIR VALUE: it trades above our $41.00 fair value estimate, 60.90% revenue growth.
Fair value range in USD, drawn from the 2026-07-19 screen. The gold marker is the market price at the same screen. The price runs 0.1% above the base estimate.
Third-party analyst targets: 13 covering, consensus Hold. The average target sits −0% from the screen price.
Reading the gap · Our model and the Street both land near the screened price: fairly valued, with no strong edge either way.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-07-19 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsBiotech firm priced exactly at fair value
Picture a commercial-stage drug maker finally turning high unmet needs into real sales. Apellis has delivered 61% revenue growth and a 12% profit margin while posting a striking 46% return on equity. Those numbers explain why the shares sit right at our calculated fair value with zero margin of safety.
The business clears our ethical screen and the analyst consensus lines up with a hold rating and a median target matching the current price. Forward earnings are still negative, however, so the strong recent profitability has yet to translate into sustained positive forecasts.
Risk sits in the usual biotech uncertainties around future trial outcomes and reimbursement, plus the fact that a negative forward multiple leaves little room for disappointment. The market is not offering a bargain or a clear overvaluation at these levels. Analysis, not advice.
| Forward P/E | -130.5x |
| Trailing P/E | 38.4xexpensive: the price assumes strong growth ahead |
| EPS, trailing | 1.07 |
| EPS, forward | -0.40 |
| Revenue growth | +60.9%growing very fast |
| Profit margin | 12.1%thin but positive margins |
| Return on equity | 46.0%an exceptional return on shareholder capital |
| FCF yield | -1.21% |
| Debt to equity | 1.15a meaningful debt load worth watching |
| Current ratio | 3.63comfortably covers its short-term bills |
| Beta | -0.25barely tracks the market's swings |
| Short interest, float | 0.13% |
| 52-week range | 16.61 - 41.14 |
| Market cap | $5.3B |
| Employees | 733 |
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Titan Case StudyOur full written analysis of APLS: APLS Case Study → 2026-07-02
Where & How to TradeAPLS trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
2026-10-27
Accumulation $41.03
+0.0% Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 57% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 151%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (13 analysts) rates it hold, with a mean price target of $41.
2026-10-12
Accumulation $41.03
+0.0% Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 57% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 151%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (13 analysts) rates it hold, with a mean price target of $41.
2026-10-02
Accumulation $41.03
+0.0% Entry 8
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 57% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 151%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (13 analysts) rates it hold, with a mean price target of $41.
2026-09-21
Accumulation $41.03
+0.0% Entry 7
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 57% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 151%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (13 analysts) rates it hold, with a mean price target of $41.
2026-08-21
Accumulation $41.03
+0.0% Entry 6
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 57% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 151%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (13 analysts) rates it hold, with a mean price target of $41.
2026-07-21
Accumulation $41.03
+0.0% Entry 5
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 57% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 151%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (13 analysts) rates it hold, with a mean price target of $41.
2026-07-18
Accumulation $41.03
+0.0% Entry 4
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 57% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 151%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (13 analysts) rates it hold, with a mean price target of $41.
2026-07-17
Accumulation $41.03
+0.0% Entry 3
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score (94). The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 57% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 151%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (13 analysts) rates it hold, with a mean price target of $41.
2026-07-03
Accumulation $41.03
+0.0% Entry 2
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score (94). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02
Accumulation $41.03
Entry 1
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with near-perfect ethical score (94). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish MarketBeat · 22 May 2026
- Biogen’s Apellis Deal And Alzheimer’s Trial Shift Focus Beyond Price Simply Wall St. · 18 May 2026
- Biogen completes $5.3B Apellis Pharmaceuticals acquisition Quartz · 15 May 2026
- Compared to Estimates, Apellis Pharmaceuticals (APLS) Q1 Earnings: A Look at Key Metrics Zacks · 7 May 2026
- Apellis Pharmaceuticals, Inc. (APLS) Tops Q1 Earnings and Revenue Estimates Zacks · 7 May 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
PTCTPTC Therapeutics, Inc.
ORKAOruka Therapeutics, Inc.
MANEVeradermics, Incorporated
ERASErasca, Inc.
COGTCogent Biosciences, Inc.
SRRKScholar Rock Holding Corporation
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-29 | BAUMAL CAROLINE | Officer | 900 | · | |
| 2026-04-17 | SULLIVAN TIMOTHY EUGENE | Chief Financial Officer | 11,096 | · | |
| 2026-03-11 | FRANCOIS CEDRIC | Chief Executive Officer | 64,869 | · | |
| 2026-02-27 | DOLSTEN MIKAEL G | Director | 14,312 | · | |
| 2026-02-11 | DELONG MARK JEFFREY | Officer | 368 | $8,153 | |
| 2026-02-03 | FRANCOIS CEDRIC | Chief Executive Officer | 8,840 | $33,238 | |
| 2026-01-28 | NICHOLSON NUR | Chief Technology Officer | 45,220 | · | |
| 2026-01-28 | CHOPAS JAMES GEORGE | Officer | 16,150 | · | |
| 2026-01-28 | DELONG MARK JEFFREY | Officer | 36,606 | · | |
| 2026-01-28 | BOUCHER KELLEY | Officer | 30,146 | · |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $40.85 | +0.5% | · | $1,005 | +0.5% |
| 2 months | $18.87 | +117.4% | · | $2,174 | +117.4% |
| 3 months | $21.70 | +89.1% | · | $1,891 | +89.1% |
| 6 months | $20.33 | +101.8% | · | $2,018 | +101.8% |
| 1 year | $16.36 | +150.8% | · | $2,508 | +150.8% |
| 2 years | $41.92 | -2.1% | · | $979 | -2.1% |
| 3 years | $87.68 | -53.2% | · | $468 | -53.2% |
| 5 years | $44.26 | -7.3% | · | $927 | -7.3% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever APLS does next, these words stay.
Membership
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.